17 May 2016 - EMA has published its 2015 annual report.

The EMA 2015 annual report published today focuses on the Agency’s core tasks which include the evaluation of medicines, support to research and development of new and innovative treatments and the monitoring of the benefits and risks of medicines in real life.

In 2015, the Agency recommended marketing authorisation for 93 medicines for human use, which include 39 new active substances, and 14 medicines for veterinary use, including seven new active substances.

Approximately one in two applicants who received a positive opinion for their medicine had received scientific advice from EMA during the development phase of their product; this figure rises to 85% for medicines containing a new active substance. Scientific advice is EMA’s key tool to promote the collection of high quality data on the benefits and risks of medicines.

For more details, go to: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/05/news_detail_002531.jsp&mid=WC0b01ac058004d5c1